US OKs Datascope's second dialysis access product:
This article was originally published in Clinica
Datascope has received US clearance to sell its second product for the dialysis access market. ProGuide is a chronic dialysis catheter for connecting a patient with end stage renal disease to a dialysis machine. Chronic dialysis catheters have an estimated worldwide market of more than $100m, said the Montvale, New Jersey firm. The company's first entered the dialysis access market in the US in March this year, when it launched its ProLumen thrombectomy device for removing blood clots from blocked dialysis access sites.
You may also be interested in...
Pfizer's third US FDA warning letter since 2018 goes to injectables site in Vizag, India; tells the company to up its game in sterility testing and in the microbiology lab.
Gilead lands on Second Genome as its first partner to apply microbiome analysis to pipeline assets to look for biomarkers. Companies also team up on GI drug discovery.
The US FDA released five device-related close-out letters in March.